Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 23 hours ago

Indications

Tirofiban Hydrochloride is used to lower the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). These events are counted together as one combined endpoint: death, myocardial infarction, or refractory ischemia/repeat cardiac procedure.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. This is the main receptor on the platelet surface that takes part in platelet aggregation. When Tirofiban is given intravenously, it inhibits ex vivo platelet aggregation, and the effect depends on the dose and the concentration.

With the PRISM-PLUS regimen, the patient gets 0.4 mcg/kg/min over 30 minutes, followed by a maintenance infusion of 0.1 mcg/kg/min. Inhibition of platelet aggregation of >90% is reached by the end of the 30-minute infusion. With the recommended regimen of 25 mcg/kg followed by a maintenance infusion of 0.15 mcg/kg/min, >90% inhibition is reached within 10 minutes.

The inhibition of platelet aggregation is reversible once the Tirofiban infusion is stopped.

Pregnancy & Breastfeeding

Tirofiban is Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. In pregnant rats and rabbits, tirofiban has been shown to cross the placenta. Tirofiban HCl was given intravenously at doses up to 5 mg/kg/day (about 5 times the maximum recommended daily human dose for rats and 13 times for rabbits, compared on a body surface area basis), and no harm to the fetus was found.

Nursing mothers: it is not known whether tirofiban is excreted in human milk. Significant levels of tirofiban were present in rat milk, though. Many drugs pass into human milk, and there is a chance of adverse effects on the nursing infant, so nursing should be stopped or AGGRASTAT should be stopped.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Give 25 mcg/kg intravenously within 5 minutes, then continue with 0.15 mcg/kg/min. For patients with serum creatinine ≤60 mL/min, the continuing rate is 0.075 mcg/kg/min. The infusion can run for up to 18 hours. Pediatric use: safety and effectiveness in pediatric patients have not been established. Important administration instructions: Tear off the foil overpouch to open the container. The plastic may look somewhat opaque because it absorbs moisture during sterilization, and this opacity fades gradually. Squeeze the inner bag firmly to check for leaks. If you find any leak, or if sterility is in doubt, discard the solution. The solution must be clear and the seal intact before use. Hang the container from its eyelet support, take the plastic protector off the outlet port, and attach a conventional administration set. AGGRASTAT can be given in the same intravenous line as atropine sulfate, dobutamine, dopamine, epinephrine hydrochloride (HCl), famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl. It must not go through the same IV line as diazepam. Don't add other drugs to the bag, and don't remove solution from it directly with a syringe. Plastic containers should not be used in series connections, because air can be drawn from the first container once it is empty of solution, and this can result in air embolism. Throw away any unused portion left in the bag.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.